Evidence map›Paper›PMID 39583926›Full record

ArticleiScience2024

Tumor stage-driven disruption of NK cell maturation in human and murine tumors.

Jules Russick, Carine Torset, Dan Sun, Solenne Marmier, Nicolas Merle, Elodie Voilin, Nathalie Josseaume, Maxime Meylan, Isaïas Hernandez, Pierre-Emmanuel Foy and 7 more

Abstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jules RussickINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Carine TorsetINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Dan SunCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Solenne MarmierINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Nicolas MerleINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Elodie VoilinINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Nathalie JosseaumeINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Maxime MeylanINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Isaïas HernandezINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Pierre-Emmanuel FoyINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Pierre-Emmanuel JoubertINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Marco AlifanoINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Audrey LupoINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Sophie SiberilINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Niklas K BjörkströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Diane DamotteINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.
Isabelle CremerINSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Team "Inflammation, Complement and Cancer", 75006 Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells play a pivotal role against cancer, both by direct killing of malignant cells and by promoting adaptive immune response though cytokine and chemokine secretion. In the lung tumor microenvironment (TME), NK cells are scarce and dysfunctional. By conducting single-cell transcriptomic analysis of lung tumors, and exploring pseudotime, we uncovered that the intratumoral maturation trajectory of NK cells is disrupted in a tumor stage-dependent manner, ultimately resulting in the selective exclusion of the cytotoxic subset. Using functional assays, we observed intratumoral NK cell death and a reduction in cytotoxic capacities depending on the tumor stage. Finally, our analyses of human public dataset on lung cancer corroborate these findings, revealing a parallel dysfunctional maturation process of NK cells during tumor progression. These results highlight additional mechanisms by which tumor cells escape from NK cell cytotoxicity, therefore paving the way for tailored therapeutic strategies.

Indexed as

Biological sciencesCancerCancer systems biologyImmunologyNatural sciencesSystems biology

Identifiers

PMID39583926
PMCPMC11585790

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.